The Biden administration is targeting diabetes treatment Jardiance and nine other medications for Medicare’s first-ever drug price negotiations as it seeks to lower medical costs for Americans.
Analysts expect Johnson & Johnson’s Xarelto blood thinner and Indianapolis-based Eli Lilly and Co.’s Jardiance for diabetes to be among the medications chosen.
The pharmaceutical company has launched 20 drugs in the past decade to treat diseases from arthritis and psoriasis to diabetes and cancer. In recent months, Lilly has overtaken every competitor to become the most valuable drugmaker in the world.
The list is expected to arrive within the next two weeks, and industry experts believe it will include some of the most widely prescribed treatments for arthritis, blood disorders, heart disease and diabetes.
Some anesthesiologists in the U.S. and Canada say they’ve seen growing numbers of patients on the weight-loss drugs who inhaled food and liquid into their lungs while sedated.
Thursday’s decision means settlement money meant for thousands of victims and their relatives and for local and state governments could be delayed.
Much of the excitement is due to strong results from Mounjaro, which hit the market in June 2022 as a treatment for Type 2 diabetes and rang up $979.7 million in the quarter.
The Indianapolis-based pharmaceutical company’s first-quarter performance was driven by strong sales of leading drugs for diabetes, cancer and other diseases.
Indiana University Health’s 70,000-square-foot pharmacy hub and distribution center in Plainfield has enough pills, lotions, and infusible and injectable drugs under one roof to supply its 16 hospitals and hundreds of clinics for weeks.
The fallout from a Pfizer factory being damaged by a tornado could put even more pressure on already-strained drug supplies at U.S. hospitals, experts say.
If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after rival Leqembi. Both drugs pose a serious safety concern—brain swelling and bleeding.
More than 110,000 Hoosiers suffer from Alzheimer’s disease, which robs people of their memories and abilities to do daily tasks, and is the nation’s sixth-leading cause of death.
With the acquisition of Versanis Bio, Lilly is adding another promising treatment to its weight-loss drug pipeline.
Women’s health advocates hope the decision will pave the way for more over-the-counter birth control options.
In this week’s edition of the IBJ Podcast, reporter John Russell discusses Medicare’s new power to negotiate drug prices and its effects on patients, drug makers and the rest the health care industry. Eli Lilly and Co. would like to see some changes.
David Ricks, CEO of Indianapolis-based drugmaker Eli Lilly and Co., is turning up the volume on his concerns over a new law that would allow Medicare, for the first time, to negotiate drug prices.
Medical experts predict the pills will be popular, especially among people who want to lose weight but are fearful of needles.
The New Jersey-based company has announced two large rounds of layoffs at its Bloomington plant within six months—400 workers last December and 150 this month.
A growing roster of corporate and political foes has started to lay siege to the law, hoping to erode some of its key provisions before they can take effect.
This year is the second year Indiana has received money from a national settlement with opioid distributors and manufacturers for opioid-related harms.
